Brief: Alzinova: Positive Phase 1B Results With Vaccine Candidate Alz-101

Alzinova AB

29/11/2023 06:23

Nov 29 (Reuters) - Alzinova AB  ALZ.ST :
    * ALZINOVA ANNOUNCES POSITIVE PHASE 1B RESULTS WITH THE
VACCINE
CANDIDATE ALZ-101 AGAINST ALZHEIMER'S DISEASE
    * STUDY MET PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY
AFTER 20
WEEKS
    * PATIENTS TREATED WITH ALZ-101 RESPONDED TO TREATMENT WITH
ANTIBODY LEVELS INCREASING WITH NUMBER OF DOSES GIVEN
    * NO CASES OF ARIA-E AND ONE CASE OF ARIA-H DETECTED IN
TREATMENT
GROUPS
    * POSITIVE RESULTS SUPPORT CONTINUED CLINICAL DEVELOPMENT OF
ALZ-101, AND PREPARATIONS FOR A PLANNED PHASE 2 STUDY ARE
ONGOING

Source text for Eikon:  ID:nMFN6DVXzB 
Further company coverage:  ALZ.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))